MarketInOut Stock Screener Log In | Sign Up
 

Roivant Sciences Ltd

NASDAQ • Healthcare • Biotechnology • Quote as of 05/22/2026
Roivant Sciences Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization21,945 mln
Float545 mln
Earnings Date08/17/2026

Beneish M-Score

-3.58
Highly reliable

1-Year Forecast

36.12
Attractive

Relative Strength

86 / 100
Strongly outperforming

Debt / Equity

0.02
Debt-free

ROE

-6.75
Negative

Dividend Yield

0.00%
No dividend

Business Description

Roivant Sciences is a London-based biopharmaceutical company founded in 2014 that discovers, develops, and brings to market new medicines and drug delivery technologies. The company is advancing several treatment candidates targeting autoimmune and inflammatory conditions such as rheumatoid arthritis, lupus, and myasthenia gravis, as well as pulmonary hypertension linked to lung disease. Roivant also develops platforms designed to improve how medicines are delivered into the body.

Key Fundamentals

EPS-0.54
ROE-6.75
RPS0.01
ROIC-189
ROA-5.66
EBITDA, mln-1,282
EV / EBITDA-15.00
EV / EBIT-14.96
Revenue, mln8.26
EV / Revenue2,328

Financial Strength

Altman Z-Score33.18
Beneish M-Score-3.58
1-Year Target Price36.12
Short Ratio5.37
Short % of Float4.99

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.29% 69 / 100   
1 Month 6.47% 79 / 100   
2 Months 13.27% 79 / 100   
6 Months 47.3% 90 / 100   
1 Year 175% 95 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us